此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Omega-3 Supplementation on Motor Performance and Bone Turnover Markers in Women: A Pilot Study (OMEGA3-FEMALE)

2026年11月9日 更新者:Aleksandra Sarachman、Wroclaw University of Health and Sport Sciences

Effects of Omega-3 Fatty Acid Supplementation on Selected Measures of Motor Performance and Bone Turnover Markers in Female Soccer Players and Women With Low Physical Activity: A Randomized, Double-Blind, Placebo-Controlled - Pilot Study

The aim of this pilot study is to assess the effects of 10 weeks of omega-3 fatty acid supplementation on selected motor performance parameters, bone turnover markers, regulators of bone remodeling, and bone mineral density in female soccer players and women with low levels of physical activity. Changes in the erythrocyte omega-3 fatty acid profile, including EPA and DHA levels and the Omega-3 Index, will also be assessed, along with potential differences in response to supplementation between the two populations.

This will be an interventional, randomized, double-blind, placebo-controlled study. A total of 40 women aged 18-35 years will be enrolled: 20 female soccer players and 20 women with low levels of physical activity. Within each population, participants will be randomly allocated in a 1:1 ratio to the omega-3 supplementation or placebo group, yielding four parallel study groups. Over 10 weeks, participants assigned to omega-3 will take three capsules daily providing 1,677 mg of EPA and 687 mg of DHA. Participants assigned to placebo will take three capsules daily providing a total of 3,000 mg of MCT oil.

Assessments will be performed at three time points: T0 (baseline, before the start of supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). Assessments will include handgrip strength, back muscle strength, lower-limb power assessed by vertical jump testing, bone turnover markers and regulators of bone remodeling, body composition and bone mineral density measured by DXA, the erythrocyte fatty acid profile, selected hormonal parameters, and dietary intake.

The effects of supplementation will be evaluated by assessing changes in the measured parameters at weeks 5 and 10 relative to baseline (T0). The magnitude of these changes will also be compared between the omega-3 and placebo groups, taking participants' level of physical activity into account.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

Omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are involved in numerous physiological processes, including regulation of inflammatory responses and the functioning of skeletal muscle and bone tissue. However, scientific evidence regarding the effects of omega-3 supplementation on physical performance and bone metabolism remains inconclusive, particularly among physically active women. This pilot study will assess responses to a controlled supplementation intervention in female soccer players and women with low levels of physical activity.

The study is interventional, randomized, placebo-controlled, and double-blind. It will include 40 women aged 18-35 years: 20 female soccer players and 20 women with low levels of physical activity. Randomization will be conducted separately within each population in a 1:1 ratio, resulting in four groups: female soccer players receiving omega-3, female soccer players receiving placebo, women with low levels of physical activity receiving omega-3, and women with low levels of physical activity receiving placebo. Treatment allocation will remain concealed from participants, outcome assessors, and data analysts until study completion and database lock.

For 10 weeks, participants in the active supplementation groups will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily, providing 3,000 mg of concentrated fish oil, including 1,677 mg of EPA and 687 mg of DHA. Participants in the placebo groups will take three NOW Foods MCT Oil 1000 mg capsules daily, providing 3,000 mg of MCT oil. Supplement adherence and any adverse events will be monitored using participant records, contact with the research team, and counts of unused capsules.

Assessments will be conducted at three time points: T0 (baseline, before supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). The T0 assessment will establish baseline values for the measured parameters, providing a reference for evaluating changes during the intervention. At each time point, motor performance will be assessed using handgrip strength, back muscle strength, and vertical jump tests. Body composition and bone mineral density will be assessed by dual-energy X-ray absorptiometry (DXA). Blood measurements will include the erythrocyte fatty acid profile and Omega-3 Index, estradiol and progesterone, and bone metabolism markers P1NP, CTX, OPG, RANKL, SOST, and DKK-1. Data on health status, menstrual cycle, hormonal contraception, physical activity, dietary intake, and anthropometry will also be collected.

The primary scientific aim is to assess the effects of omega-3 fatty acid supplementation compared with placebo on selected motor performance parameters, markers of bone turnover and remodeling, and bone mineral density. Intervention effects will be evaluated by comparing values at T1 and T2 with baseline values at T0, including comparisons between the omega-3 and placebo groups. Supplementary analyses will assess changes in EPA and DHA levels and potential differences in response between female soccer players and women with low levels of physical activity.

研究类型

介入性

注册 (估计的)

40

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Lower Silesian Voivodeship
      • Wroclaw、Lower Silesian Voivodeship、波兰、51-612
        • 招聘中
        • Wroclaw University of Health and Sport Sciences
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 35年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

Female soccer players:

  • Female sex, age 18-35 years.
  • Regular sports training for more than 10 hours per week.
  • Active participation in league competitions.
  • No medical contraindications to participation.
  • No injury resulting in a training interruption longer than 2 weeks during the 3 months before the study.
  • Written informed consent to participate, undergo blood collection, and have laboratory tests performed.

Women with low levels of physical activity:

  • Female sex, age 18-35 years.
  • Physical activity below 150 minutes per week.
  • Body mass index (BMI) between 18.5 and 24.9 kg/m².
  • No medical contraindications to participation.
  • Written informed consent to participate, undergo blood collection, and have laboratory tests performed.

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Use of supplements containing omega-3 fatty acids within the 3 months before the study.
  • Allergy or hypersensitivity to fish, fish oil, gelatin, or other ingredients of the active supplement or placebo.
  • Diseases or use of medications that may substantially affect lipid metabolism, muscle function, or bone metabolism.
  • Neurological disorders.
  • Bleeding disorders or treatment considered by a physician to increase the risks associated with supplementation or blood sampling.
  • Injury or symptoms that prevent safe performance of motor tests.
  • Other contraindications identified during medical screening.
  • Failure to provide written informed consent to participate, undergo blood collection, and have the planned analyses performed.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1 - Female Soccer Players: Omega-3

Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks. The daily dose will provide 3,000 mg of concentrated fish oil containing 2,457 mg of omega-3 fatty acids, including 1,677 mg of EPA and 687 mg of DHA.

安慰剂比较:Arm 2 - Female Soccer Players: Placebo

Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks, providing 3,000 mg of MCT oil per day. The placebo contains neither EPA nor DHA.

实验性的:Arm 3 - Women With Low Levels of Physical Activity: Omega-3

Women with low levels of physical activity (less than 150 minutes per week) will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks. The daily dose will provide 3,000 mg of concentrated fish oil containing 2,457 mg of omega-3 fatty acids, including 1,677 mg of EPA and 687 mg of DHA.

安慰剂比较:Arm 4 - Women With Low Levels of Physical Activity: Placebo

Women with low levels of physical activity (less than 150 minutes per week) will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks, providing 3,000 mg of MCT oil per day. The placebo contains neither EPA nor DHA.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Handgrip Strength
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Handgrip strength will be assessed using a T.K.K. 5001 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Back Muscle Strength
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Back muscle strength will be measured using a T.K.K. 5402 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Vertical Jump Performance
大体时间:: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Lower-limb power will be assessed using vertical jump testing with the OptoJump system (Microgate) at T0, T1, and T2. Changes in vertical jump results after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum P1NP Concentration
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Serum concentrations of the N-terminal propeptide of type I procollagen (P1NP), a marker of bone formation, will be determined by ELISA at T0, T1, and T2. Changes in P1NP concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum CTX Concentration
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Serum concentrations of the C-terminal telopeptide of type I collagen (CTX), a marker of bone resorption, will be measured at T0, T1, and T2. Changes in CTX concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Bone Mineral Density
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Whole-body bone mineral density (BMD) will be assessed by DXA using a Lunar iDXA scanner (GE HealthCare) at T0, T1, and T2. Changes in BMD after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

次要结果测量

结果测量
措施说明
大体时间
Change in Serum Osteoprotegerin Concentration
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Osteoprotegerin (OPG), a regulator of bone remodeling, will be measured in serum using ELISA at T0, T1, and T2. Changes in OPG concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum RANKL Concentration
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Receptor activator of nuclear factor kappa-B ligand (RANKL) will be measured in serum using ELISA at T0, T1, and T2. Changes in RANKL concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum Sclerostin Concentration
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Sclerostin (SOST) will be measured in serum using ELISA at T0, T1, and T2. Changes in SOST concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum DKK-1 Concentration
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Dickkopf-1 (DKK-1) protein will be measured in serum using ELISA at T0, T1, and T2. Changes in DKK-1 concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Erythrocyte EPA Content
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The proportion of eicosapentaenoic acid (EPA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in EPA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Erythrocyte DHA Content
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The proportion of docosahexaenoic acid (DHA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in DHA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Omega-3 Index
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The Omega-3 Index will be calculated from the combined proportion of EPA and DHA in the erythrocyte fatty acid profile at T0, T1, and T2. Changes in the Omega-3 Index after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in the Erythrocyte Omega-6 to Omega-3 Ratio
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The omega-6 to omega-3 fatty acid ratio will be derived from the erythrocyte fatty acid profile measured by GC-FID at T0, T1, and T2. Changes in the omega-6 to omega-3 ratio after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

其他结果措施

结果测量
措施说明
大体时间
Change in Dietary Intake
大体时间:T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Dietary intake will be assessed using a 72-item food frequency questionnaire and a 7-day food diary, including the intake of omega-3 fatty acids. Assessments will be conducted at T0, T1, and T2. Changes in dietary intake and omega-3 fatty acid consumption after 5 and 10 weeks of supplementation relative to baseline will be analyzed.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 学习椅:Anna Książek, PhD, DSc、Department of Biological Principles of Physical Activity Wroclaw University of Health and Sport Sciences, Poland 35 Paderewskiego Avenue, 51-612 Wrocław,

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月27日

初级完成 (估计的)

2027年1月31日

研究完成 (估计的)

2027年2月28日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • OMEGA3-FEMALE-PILOT-2026

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared with external researchers or deposited in public repositories, even after removal of direct identifiers. Access to the data will be restricted to authorized members of the research team. Study results will be published only in aggregate form, without disclosing participants' identities.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.